logo
Share SHARE
FONT-SIZE Plus   Neg

AVEO Oncology: FDA Panel To Review Tivozanib For Treatment Of Advanced RCC

AVEO Oncology (AVEO) and Astellas Pharma Global Development Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced Wednesday that the U.S. Food and Drug Administration's or FDA Oncologic Drugs Advisory Committee or ODAC will review the company's New Drug Application or NDA for tivozanib for the treatment of patients with advanced renal cell carcinoma or RCC during the morning session of its meeting on May 2, 2013.

ODAC reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer, and makes recommendations to the Commissioner of Food and Drugs. According to the timelines established by the Prescription Drug User Fee Act or PDUFA, the review of the NDA is expected to be complete by July 28, 2013.

In November 2012, AVEO and Astellas announced that the FDA accepted for filing the NDA for tivozanib with the proposed indication for the treatment of patients with advanced RCC. The NDA includes results of the global Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) trial, a randomized superiority-designed pivotal trial evaluating the efficacy and safety of tivozanib compared to sorafenib, an approved targeted agent, in 517 patients with advanced RCC, as well as data from 16 additional AVEO-sponsored studies involving over 1,000 subjects who received tivozanib. Tivozanib is an investigational medicine and is not currently approved in any country.

Advanced RCC, or kidney cancer, is the ninth most commonly diagnosed cancer in men and women in the U.S.1 Worldwide it is estimated that more than 250,000 people are diagnosed and more than 100,000 people die from the disease each year.2 RCC accounts for more than 90 percent of all kidney cancers.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
L'Oreal Co (LRLCY.PK) on Thursday reported an increase in profit for the first half of 2015, driven by growth in North America and new markets, and favorable currency helping results. The French cosmetics company said that on the back of comprehensive growth, it is making investments in the digital... Starwood Hotels & Resorts Worldwide, Inc. (HOT) said Thursday that its second quarter profit fell 11% from last year, hurt by lower revenue as well as restructuring and special charges. However, the company's quarterly earnings per share, excluding items, came in above analysst' expectations as did... Home buyers seem to be reaping the benefits of attractive mortgage rates, with the average 30-year fixed mortgage rate ducking just under four percent, a report from Freddie Mac said Thursday.
comments powered by Disqus
RELATED NEWS
Trade AVEO now with 
Follow RTT